Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

3-Iodobenzylguanidine 13lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4Temozolomide 4Specimen Handling 4anlotinib 3Magnetic Resonance Spectroscopy 3Everolimus 3pegfilgrastim 2olaparib 2cabozantinib 2belzutifan 2Radiotherapy 2Phenoxybenzamine 2Nivolumab 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1tipifarnib 1temsirolimus 1talazoparib 1spartalizumab 1pentetreotide 1penpulimab 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × copper dotatate CU-64 × CNS × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡